Diabetic metastatic castration resistant prostate cancer patients administered mefformin during docetaxel chemotherapy have improved prostate cancer-specific and overall survival

被引：1
|
作者：
Mayer, Michelle
Klotz, Laurence
Venkateswaran, Vasundara
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1434
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
    Halabi, Susan
    Armstrong, Andrew J.
    Sartor, Oliver
    de Bono, Johann
    Kaplan, Ellen
    Lin, Chen-Yen
    Solomon, Nicole C.
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 3944 - +
  • [42] IMPROVED SURVIVAL PROSPECTS FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Kirby, Roger S.
    Fitzpatrick, John M.
    BJU INTERNATIONAL, 2011, 107 (05) : 697 - 700
  • [43] Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy
    Periman, P. O.
    Sonpavde, G.
    Bernold, D. M.
    Weckstein, D. J.
    Williams, A.
    Zhan, F.
    Boehm, K. A.
    Asmar, L.
    Hutson, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Nomograms and scoring system for forecasting overall and cancer-specific survival of patients with prostate cancer
    Zhou, Yuan
    Lin, Changming
    Zhu, Lian
    Zhang, Rentao
    Cheng, Lei
    Chang, Yuanyuan
    CANCER MEDICINE, 2023, 12 (03): : 2600 - 2613
  • [45] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer
    Gyawali, Bishal
    Koomulli-Parambil, Sahadudheen
    Iddawela, Mahesh
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 102 : 118 - 124
  • [47] Management of metastatic castration-resistant prostate cancer following docetaxel
    Beuzeboc, Philippe
    Ropert, Stanislas
    Goldwasser, Francois
    Zerbib, Marc
    BULLETIN DU CANCER, 2012, 99 : S66 - S72
  • [48] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
    Caffo, Orazio
    Lo Re, Giovanni
    Sava, Teodoro
    Buti, Sebastiano
    Sacco, Cosimo
    Basso, Umberto
    Zustovich, Fable
    Lodde, Michele
    Perin, Alessandra
    Facchini, Gaetano
    Veccia, Antonello
    Maines, Francesca
    Barile, Carmen
    Fratino, Lucia
    Gernone, Angela
    De Vivo, Rocco
    Pappagallo, Giovanni L.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2015, 11 (06) : 965 - 973
  • [49] Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Sternberg, C. N.
    Molina, A.
    North, S.
    Mainwaring, P.
    Fizazi, K.
    Hao, Y.
    Rothman, M.
    Gagnon, D. D.
    Kheoh, T.
    Haqq, C. M.
    Cleeland, C.
    de Bono, J. S.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1017 - 1025
  • [50] KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
    Schaefer, Georg
    Bednarova, Nikola
    Heidenreich, Axel
    Klocker, Helmut
    Heidegger, Isabel
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 3946 - +
12345